From 2 KEY POINTS 1. Iron deficiency results in symptom improvement in CEP and could be considered as a novel therapeutic approach for this disease. 2. CEP marrow cells demonstrated improved growth and erythroid differentiation in vitro under conditions of relative iron restriction. ABSTRACT Congenital erythropoietic porphyria (CEP) is an autosomal recessive disorder of heme synthesis characterized by reduced activity of uroporphyrinogen III synthase (UROS) and the accumulation of non-physiologic isomer I porphyrin metabolites, resulting in ineffective erythropoiesis and devastating skin photosensitivity. Management of the disease primarily consists of supportive measures. Increased activity of 5-aminolevulinate synthase 2 (ALAS2) has been shown to adversely modify the disease phenotype. Herein we present a patient with CEP who demonstrated a remarkable improvement in disease manifestations in the setting of iron deficiency. Hypothesizing that iron restriction 7 participate in their care, and for providing biologic specimens for further study.
improved her symptoms by decreasing ALAS2 activity and subsequent porphyrin production, we treated the patient with off-label use of deferasirox to maintain iron deficiency, with successful results. We confirmed the physiology of her response with marrow culture studies.
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INTRODUCTION
CEP is an autosomal recessive disorder resulting from mutations in the UROS gene, which encodes the fourth enzyme in the heme synthetic pathway. 1 Reduced UROS activity leads to non-enzymatic conversion of hydroxymethylbilane to isomer I porphyrin metabolites, which accumulate in late erythroid precursors, reticulocytes and red cells, resulting in ineffective erythropoiesis, hemolysis and splenomegaly; and which disseminate into tissues such as skin to cause severe photosensitivity. Management is largely comprised of sun avoidance, splenectomy and supportive measures, and in some patients hematopoietic stem cell transplantation has been effective. [2] [3] [4] Over 45 mutations in UROS have been identified 5 and disease severity correlates with the degree that enzymatic activity is reduced. [6] [7] [8] [9] As evidence that additional factors may influence the disease phenotype, a gain-of-function mutation in ALAS2, which encodes the first and rate limiting enzyme in the heme biosynthetic pathway, has been associated with more severe CEP symptoms. 10 This raises the question whether decreased ALAS2 activity would lessen disease severity by decreasing porphyrin production. Deficiency of iron impedes heme synthesis upstream of UROS by decreasing ALAS2 translation via binding of an iron regulatory protein to an iron-responsive element in the 5' UTR of ALAS2 mRNA, suggesting a possible therapeutic role for iron restriction in the treatment of erythropoietic porphyrias. 11, 12 
METHODS

Bone marrow cell cultures
Marrow was obtained post-mortem from the CEP patient #1 with parental consent.
Marrow was also obtained from her younger sister (patient #2) with IRB approval.
Mononuclear cells were cultured adapting the protocol of Giarratana 13 
Flow cytometry
Cells were analyzed and sorted by BD FACS Canto II or FACAria flow cytometers with Cell Quest software on culture days 10, 13, and 17. Anti-CD3, anti-C11b, and anti-CD19 were used to deplete non-erythroid cells, and anti-CD36, anti-CD235 (glycophorin A), and anti-CD71 (all from BD Pharmingen) were used to monitor erythroid differentiation. An Annexin V-FITC Apoptosis Detection Kit I with propidium iodide staining solution was used for apoptosis assays.
RNA and protein studies
Total RNA was isolated using TRIzol (Ambion) and cDNA was synthesized with reverse transcriptase in SuperScript First-Strand Synthesis System (Bio-Rad). Multiplex quantitative PCR was performed with KAPA Probe Fast Bio-Rad iCycler qPCR Kits.
Human cDNA clones (OriGene) were used as standards. Probes were labeled with FAM, HEX, and Cy5 (IDT). The results were expressed as copy numbers normalized by β -actin in 50 ng total RNA. Western blots of cell lysates were probed with rabbit anti-ALAS2 (Santa Cruz), mouse monoclonal anti-β-globin (Abcam) and anti-β-actin (Sigma)
antibodies.
RESULTS AND DISCUSSION
Clinical Data.
A female of Alaskan Native descent (patient #1) was diagnosed with CEP at 12 months of age after presenting with red urine, discolored teeth and blisters. A younger sister (patient #2) would later be diagnosed with CEP. Genetic testing revealed compound heterozygosity for previously described C73R and A104V mutations in UROS. Since To determine the effect of iron restriction on erythroid cell survival and differentiation, normal cells and CEP marrow cells were cultured in media containing different ratios of holo-Tf and apo-Tf media, as described in the Methods. The greatest numbers of CEP cells were found in conditions of partial iron restriction (50% holo-Tf), versus higher or lower holo-Tf concentrations ( Figure 2C ). With 50% holo-Tf, more CEP cells also Figure 2E .
Discussion
Since CEP symptoms correlate with the degree of porphyrin excess, 14 therapeutic interventions are often aimed at reducing levels of circulating porphyrins. Therapies such as hypertransfusion [15] [16] and oral charcoal [17] [18] [19] [20] have had limited success. Some mutations in UROS result in protein instability and degradation via the proteasome. 21 Consistent with this, bortezomib has been shown to reduce porphyrin accumulation and photosensitivity in a murine model of CEP, though a trial in humans has yet to be initiated. 22 Iron chelation has been used to ameliorate the accompanying iron overload that often develops in CEP patients. 23 However, in the present case we initiated deferasirox to restrict iron availability. Our patient demonstrated a remarkable improvement in disease-related symptoms and more effective erythropoiesis with iron deficiency from both gastrointestinal losses and off-label use of deferasirox.
Iron restriction likely impedes heme synthesis upstream of UROS via decreasing ALAS2
mRNA translation ( Figure 2E ). Since the TCA cycle enzyme aconitase contains a 4Fe-4S cluster, it is also possible that decreased availability of succinyl CoA, a key substrate for the rate-limiting step in heme production, may play a role. Erythroid cells obtained from the bone marrow of this CEP patient demonstrated improved growth and differentiation in conditions of relative iron deficiency. We propose that iron restriction might therapeutically benefit other patients with CEP, and perhaps patients with other erythroid disorders involving the heme biosynthetic pathway.
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(B) Absolute numbers of erythroid cells in cultures containing 100% holo-Tf. Cultures of marrow cells from CEP patient #2 at day 10 have fewer cells than control cultures. This is mainly due to the decreased numbers of erythroid cells in stage III (19.0 x 10 5 vs. 29.6
x 10 5 ); suggesting that CEP erythroid cells die when transiting to or in stage III. All cultures were initiated (day 0) with 2.0 x 10 6 bone marrow mononuclear cells (BMMNC).
Similar results were also seen in marrow culture studies of CEP patient #1 (Supplemental 13 and 17 (not shown). Marrow culture studies of CEP patient #1 yielded similar data (Supplemental Figure 1C) . In contrast, the numbers of normal erythroid cells on culture day 10 progressively declines when iron delivery was restricted (Supplemental Figure   1D ).
(E) Expression of ALAS2 mRNA and protein in CEP cells during erythroid differentiation.
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